The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

A larger waist circumference is associated with a higher risk of all-cause mortality and decreased life expectancy. Meanwhile, the group taking Zepbound (sold as Mounjaro for weight loss in some markets) also saw greater improvements in blood pressure, blood glucose, and cholesterol levels.